SARS-CoV-2 spike-induced syncytia are senescent and contribute to exacerbated heart failure
-
Published:2024-08-05
Issue:8
Volume:20
Page:e1012291
-
ISSN:1553-7374
-
Container-title:PLOS Pathogens
-
language:en
-
Short-container-title:PLoS Pathog
Author:
Li Huilong, Wan Luming, Liu Muyi, Ma Enhao, Huang Linfei, Yang Yilong, Li Qihong, Fang Yi, Li Jingfei, Han Bingqing, Zhang Chang, Sun Lijuan, Hou Xufeng, Li Haiyang, Sun Mingyu, Qian Sichong, Duan Xuejing, Zhao Ruzhou, Yang Xiaopan, Chen Yi, Wu Shipo, Zhang Xuhui, Zhang Yanhong, Cheng Gong, Chen Gengye, Gao Qi, Xu Junjie, Hou Lihua, Wei Congwen, Zhong HuiORCID
Abstract
SARS-CoV-2 spike protein (SARS-2-S) induced cell–cell fusion in uninfected cells may occur in long COVID-19 syndrome, as circulating SARS-2-S or extracellular vesicles containing SARS-2-S (S-EVs) were found to be prevalent in post-acute sequelae of COVID-19 (PASC) for up to 12 months after diagnosis. Although isolated recombinant SARS-2-S protein has been shown to increase the SASP in senescent ACE2-expressing cells, the direct linkage of SARS-2-S syncytia with senescence in the absence of virus infection and the degree to which SARS-2-S syncytia affect pathology in the setting of cardiac dysfunction are unknown. Here, we found that the senescent outcome of SARS-2-S induced syncytia exacerbated heart failure progression. We first demonstrated that syncytium formation in cells expressing SARS-2-S delivered by DNA plasmid or LNP-mRNA exhibits a senescence-like phenotype. Extracellular vesicles containing SARS-2-S (S-EVs) also confer a potent ability to form senescent syncytia without de novo synthesis of SARS-2-S. However, it is important to note that currently approved COVID-19 mRNA vaccines do not induce syncytium formation or cellular senescence. Mechanistically, SARS-2-S syncytia provoke the formation of functional MAVS aggregates, which regulate the senescence fate of SARS-2-S syncytia by TNFα. We further demonstrate that senescent SARS-2-S syncytia exhibit shrinked morphology, leading to the activation of WNK1 and impaired cardiac metabolism. In pre-existing heart failure mice, the WNK1 inhibitor WNK463, anti-syncytial drug niclosamide, and senolytic dasatinib protect the heart from exacerbated heart failure triggered by SARS-2-S. Our findings thus suggest a potential mechanism for COVID-19-mediated cardiac pathology and recommend the application of WNK1 inhibitor for therapy especially in individuals with post-acute sequelae of COVID-19.
Funder
Development Program of China grant National Natural Science Foundation of China
Publisher
Public Library of Science (PLoS)
Reference56 articles.
1. The COVID-19 epidemic and total mortality: missed data and the incoming epidemiology];E Paci;Epidemiol Prev,2023 2. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC);ZA Sherif;Elife,2023 3. Post-acute sequelae of COVID-19 (PASC): a meta-narrative review of pathophysiology, prevalence, and management;B Munipalli;SN Compr Clin Med,2022 4. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms;AD Proal;Front Microbiol,2021 5. COVID-19 and the heart;A Xanthopoulos;World J Clin Cases,2022
|
|